Session » Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1399

Assessing a Conceptual Framework of Quality of Life in a Cutaneous Lupus Erythematosus Population

9:00AM-11:00AM: Abstract Number: 1405

Assessment of the Psychometric Properties of Patient-Reported Outcomes of Depression in SLE

9:00AM-11:00AM: Abstract Number: 1381

Association of Omeract Core Domains of Pain and Function with Patient Satisfaction after Total Joint Replacement

9:00AM-11:00AM: Abstract Number: 1388

Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community

9:00AM-11:00AM: Abstract Number: 1380

Complications Following Total Hip Arthroplasty in Inflammatory Versus Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1395

Could the Shortening of the Electronic Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) Questionnaire Improve Its Metric Properties?

9:00AM-11:00AM: Abstract Number: 1392

Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1389

Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1394

Development and Pilot of a Patient Satisfaction Scale in Rheumatology

9:00AM-11:00AM: Abstract Number: 1407

Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1400

Effects of Childhood-Onset SLE on Academic Achievements and Employment in Adult Life

9:00AM-11:00AM: Abstract Number: 1409

Empowerment in Hispanic Rheumatoid Arthritis Patients: A Validation Study

9:00AM-11:00AM: Abstract Number: 1403

Estimates of Minimally Important Differences and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short-Forms Among Individuals with SLE

9:00AM-11:00AM: Abstract Number: 1382

Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 1383

Examining Cutaneous Disease Activity As an Outcome Measure for Clinical Trials in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1396

Factors Associated with Specific Quality of Life Evolution in SLE Patients: A French Prospective Longitudinal Multicenter Study

9:00AM-11:00AM: Abstract Number: 1393

Fatigue in Men and Women with Psoriatic Arthritis: An International Qualitative Study

9:00AM-11:00AM: Abstract Number: 1387

Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients

9:00AM-11:00AM: Abstract Number: 1386

Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)

9:00AM-11:00AM: Abstract Number: 1384

Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States

9:00AM-11:00AM: Abstract Number: 1390

Impact of Psoriatic Arthritis from the Patient’s Perspective in the Context of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire: An Online Global Survey

9:00AM-11:00AM: Abstract Number: 1398

Inflammatory Arthritis DMARD Adverse Effects Are Pervasive and Can Greatly Impact Quality of Life and Work and Social Roles: Initial Results from the Omeract Safety Working Group

9:00AM-11:00AM: Abstract Number: 1401

Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 1397

Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study

9:00AM-11:00AM: Abstract Number: 1406

Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?

9:00AM-11:00AM: Abstract Number: 1391

Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice

9:00AM-11:00AM: Abstract Number: 1404

Responsiveness of Promis (Patient Reported Outcomes Measurement Information System) Measures in a Multi-Racial, Multi-Ethnic Systemic Lupus Erythematosus (SLE) Cohort

9:00AM-11:00AM: Abstract Number: 1385

Subjective Well-Being Among Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1402

The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis

9:00AM-11:00AM: Abstract Number: 1408

Using Patient Reported Outcomes at Point of Care in Immune Mediated Diseases: Minimal Clinically Important Differences

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].